Technology Review - Published By MIT
Log in to My.TechnologyReview.com | Register
Advertisement
« Back 1 [2]

Monday, January 01, 2007

From the Labs: Biotechnology

Continued from page 1

By Emily Singer

smaller text tool iconmedium text tool iconlarger text tool icon

Wine Component Boosts Exercise Capacity in Mice
Resveratrol allows treated mice to run for twice as long as untreated ones

Source: "Resveratrol Improves Mitochondrial Function and Protects against Metabolic Disease by Activating SIRT1 and PGC-1a"
Marie Lagouge et al.
Cell online, November 16, 2006

RESULTS: Researchers at France's University Louis Pasteur, Strasbourg, and at Sirtris Pharmaceuticals have shown that resveratrol, a chemical component of red wine that has already been linked to longevity, protects mice against diet-induced obesity and insulin resistance and boosts their endurance, allowing them to run for twice as long as untreated animals before becoming exhausted. The researchers found that mice treated with resveratrol also had large, highly active mitochondria, the subcellular structures that convert nutrients into energy in almost all plants and animals. This effect was linked to activation of a gene called SIRT1, the mammalian equivalent of a gene known to influence life span in yeast.

WHY IT MATTERS: The findings may indicate the mechanism behind resveratrol's life-extending effects: activating SIRT1 to boost metabolic function. If scientists can understand how to regulate the biochemical pathway that causes aging, they may be able to design drugs that can stop the diseases of old age.

METHODS: Mice fed a high-fat diet were given high doses of resveratrol (either 200 or 400 milligrams per kilogram of body weight, or the equivalent of about 8,000 to 16,000 glasses of red wine). The researchers then tested the resting metabolism, exercise capacity, and insulin sensitivity of the mice. They also used electron microscopy to study the size of the mice's mitochondria and calculated differences in the expression of mitochondria-related genes in treated and nontreated mice.

NEXT STEPS: Sirtris Pharmaceuticals is conducting a clinical trial of a resveratrol­-like compound intended to treat type II diabetes.

« Back 1 [2]
January/February 2007

Would you like to read more articles from the January/February 2007 issue?

This article is from the January/February 2007 Issue of Technology Review. To read other articles from this issue simply register for My.TechnologyReview.com. It's free.

Subscribe today and save up to 41% »

Comments

Advertisement

Current Issue

Technology Review July/August 2008
The Business of Social Networks
The future of the Web is social. But can social-networking sites ever make money?
•  Subscribe
Save 41%
•  Table of Contents
•  MIT News

Magazine Services

Career Resources

MIT Technology Insider

Stories and breaking news from inside MIT about the latest research, innovations, and startups--in a convenient monthly e-newsletter. Subscribe today
Advertisement
Advertisement
Advertisement
Advertisement
TECHNOLOGY RESOURCES
Advertisement
MIT Massachusetts Institute of Technology